A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Doses of Corticosteroids.

Trial Profile

A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Doses of Corticosteroids.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Varicella zoster virus infections
  • Focus Adverse reactions; Registrational
  • Sponsors Merck & Co
  • Most Recent Events

    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 26 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Planned end date changed from 1 Sep 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top